Skip to content

Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content

Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02384655
Enrollment
30
Registered
2015-03-10
Start date
2015-03-11
Completion date
2021-09-30
Last updated
2020-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lactation, Preterms

Keywords

Preterms, Breastfeeding, Lactation, Macronutrients

Brief summary

Feeding human milk to preterm infants does reduce the risk of serious and costly neonatal intensive care unit acquired morbidity such as NEC and the late onset sepsis. It is often difficult to obtain sufficient quantities of human milk from mothers of preterm infants most of whom are breast pump-dependent for weeks or months. Mothers will try to use galactogogues in an attempt to increase milk production. Fenugreek (Trigonella foenum-graecum) seeds is the most commonly used herbal galactogogue and is a member of the pea family. Our experience at the NICU is that around 30% of preterm mothers desperately looking for ways to increase their breast milk supply will eventually took fenugreek (Hilbe) as food supplement. Although widely recommended, there is limited evidence to support the effectiveness of fenugreek as a galactogogue. The aims of this study are to evaluate whether maternal consumption of fenugreek seeds has any effect on macronutrients composition of breast milk and whether fenugreek is transferred to the infant via mother milk. In addition any changes in mother and infant health status will be assessed.

Interventions

DRUGFenugreek seed meal

3x3 capsules of fenugreek seeds per day for 14 days

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Healthy mothers 7 to 14 days postpartum, * Mothers of preterm infants under 38 weeks of gestation, * Mothers with poor milk supply documented by professional lactation consultants.

Exclusion criteria

* Mothers with mastitis, * Mothers with breast engorgement, * Mothers currently consuming Reglan, Domperidone or other drugs/herbals used to induce milk production, * Mothers who are taking medications (Diuretics, Pseudoephedrine, - Anticholinergics, Warfarin or any anticoagulant, An estrogen-containing birth control pill), * Mothers with Diabetes mellitus, * Mothers who have had breast surgery that could alter milk synthesis or production, * Mothers diagnosed with Polycystic Ovary Syndrome, * Mothers diagnosed with Asthma or atopic disease, * Mothers who are known to be allergic to peanuts or soybeans, * Mothers whose milk supply per 24 hours exceeds 600 mL, * Mothers with hypo/hyperthyroidism

Design outcomes

Primary

MeasureTime frame
Change in daily volume of expressed milkat day 0, 3, 7, 10, 14

Secondary

MeasureTime frame
Change in Macronutrient content analysis of breastmilkat day 0, 3, 7, 14

Countries

Israel

Contacts

Primary ContactRonella Marom, MD
ronellam@tlvmc.gov.il+97236925690

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026